Shareholder Campaign: Baxter International

Baxter International develops, manufactures, and markets products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions.

2011 Resolution: Transparency in Animal Use

In the fall of 2010, PETA filed a resolution requesting that Baxter issue an annual report to shareholders disclosing the number and species of animals used in-house and at contract laboratories, the number and species of animals used for explicitly required testing and basic research and development, and Baxter’s plans to reduce and phase out animal testing.

The resolution was largely the result of a whistleblower’s report to PETA stating that pigs and dogs at a Baxter laboratory were “screaming as though in terrible pain.” Baxter responded that they had conducted an internal investigation into the matter and found no basis for concerns about animal welfare. However, when PETA pressed Baxter for more information about its investigation, the company did not respond.

Negotiations with Baxter prior to the annual meeting resulted in withdrawal of the resolution when the company agreed to meet with PETA annually and address ongoing issues regarding Baxter’s animal use.

PETA’s Milestones for Animals

PETA's Milestones for

View Now

Get PETA Updates

Stay up to date on the latest vegan trends and get breaking animal rights news delivered straight to your inbox!

By submitting this form, you are agreeing to our collection, storage, use, and disclosure of your personal info in accordance with our privacy policy as well as to receiving e-mails from us.

 Ingrid E. Newkirk

“Almost all of us grew up eating meat, wearing leather, and going to circuses and zoos. We never considered the impact of these actions on the animals involved. For whatever reason, you are now asking the question: Why should animals have rights?” READ MORE

— Ingrid E. Newkirk, PETA President and co-author of Animalkind